Synthesis of a C-phosphonate mimic of maltose-1-phosphate and inhibition studies on Mycobacterium tuberculosis GlgE

Article abstract of DOI:10.1016/j.bmc.2013.12.058

The emergence of extensively drug-resistant tuberculosis (XDR-TB) necessitates the need to identify new anti-tuberculosis drug targets as well as to better understand essential biosynthetic pathways. GlgE is a Mycobacterium tuberculosis (Mtb) encoded maltosyltransferase involved in α-glucan biosynthesis. Deletion of GlgE in Mtb results in the accumulation of M1P within cells leading to rapid death of the organism. To inhibit GlgE a maltose-C-phosphonate (MCP) 13 was designed to act as an isosteric non-hydrolysable mimic of M1P. MCP 13, the only known inhibitor of Mtb GlgE, was successfully synthesized using a Wittig olefination as a key step in transforming maltose to the desired product. MCP 13 inhibited Mtb GlgE with an IC₅₀ = 230 ± 24 μM determined using a coupled enzyme assay which measures orthophosphate release. The requirement of M1P for the assay necessitated the development of an expedited synthetic route to M1P from an intermediate used in the MCP 13 synthesis. In conclusion, we designed a substrate analogue of M1P that is the first to exhibit Mtb GlgE inhibition.

Full text of DOI:10.1016/j.bmc.2013.12.058

Bioorganic & Medicinal Chemistry 22 (2014) 1404–1411
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier.com/locate/bmc
Synthesis of a C-phosphonate mimic of maltose-1-phosphate
and inhibition studies on Mycobacterium tuberculosis GlgE
⇑
Sri Kumar Veleti, Jared J. Lindenberger, Donald R. Ronning, Steven J. Sucheck
Department of Chemistry, The University of Toledo, 2801 W. Bancroft Street, MS602, Toledo, OH 43606, United States
a r t i c l e i n f o
a b s t r a c t
Article history:
The emergence of extensively drug-resistant tuberculosis (XDR-TB) necessitates the need to identify new
anti-tuberculosis drug targets as well as to better understand essential biosynthetic pathways. GlgE is a
Received 6 November 2013
Revised 16 December 2013
Accepted 26 December 2013
Available online 3 January 2014
Mycobacterium tuberculosis (Mtb) encoded maltosyltransferase involved in
a-glucan biosynthesis. Dele-
tion of GlgE in Mtb results in the accumulation of M1P within cells leading to rapid death of the organism.
To inhibit GlgE a maltose-C-phosphonate (MCP) 13 was designed to act as an isosteric non-hydrolysable
mimic of M1P. MCP 13, the only known inhibitor of Mtb GlgE, was successfully synthesized using a Wittig
olefination as a key step in transforming maltose to the desired product. MCP 13 inhibited Mtb GlgE with
Keywords:
Mycobacterium tuberculosis
GlgE
C-phosphonates
Enzyme inhibition
Maltose-1-phosphate
an IC50 = 230 24 lM determined using a coupled enzyme assay which measures orthophosphate
release. The requirement of M1P for the assay necessitated the development of an expedited synthetic
route to M1P from an intermediate used in the MCP 13 synthesis. In conclusion, we designed a substrate
analogue of M1P that is the first to exhibit Mtb GlgE inhibition.
Ó 2013 Elsevier Ltd. All rights reserved.
1. Introduction
sulfolipids.4 Most important for this paper, trehalose can be incor-
porated into a branched
a
-glucan.5 This pathway requires three
Tuberculosis (TB) is an infectious disease caused by various
strains of mycobacteria, most commonly, Mycobacterium tuberculo-
sis (Mtb)1 which is the leading cause of death in the world due to
bacterial infection. TB attacks the lungs and also affects other parts
of the body. It is easily diffused through the air when people who
have an active TB infection cough, sneeze, or otherwise transmit
their saliva through the air.2 In 2011, 5.8 million newly diagnosed
TB cases were reported to national TB control programs (NTPs) and
to the World Health Organization (WHO). In addition, there were
990,000 deaths reported.1 At one time TB was believed to be read-
ily treatable and easily eradicated, but in recent years due to pov-
erty and co-infection with HIV, extensively drug-resistant strains
(XDR) of TB have emerged which make treatment increasingly dif-
ficult. Therefore, there is an urgent need to discover targets for
treating this disease that are different from antibiotics currently
in use.
enzymes trehalose synthase (TreS), maltokinase (Pep2), and GlgE
a maltosyltransferase (Scheme 1).5 In this pathway, trehalose is
first isomerized to maltose (4-O-a-D-glucopyranosyl-D-glucose)
by TreS and then maltose is phosphorylated by Pep2 to produce
maltose-1-phosphate (M1P).6 The maltosyltransfer catalyzed by
GlgE using M1P generates linear
substrates for GlgB, which introduces
-glucan.
Kalscheuer et al. reported that inactivation of GlgE led to self-
a
-glucans that function as
a-1,6 branches into the
a
poisoning by the accumulation of phosphosugar M1P, facilitated
by a self-amplifying feedback response.6 GlgE has a unique
Trehalose, the common name of
a-D-glucopyranosyl-(1 ? 1)-a-
D-glucopyranoside, is a pivotal metabolite present in mycobacteria.
For example, it is used as mycolic acid carrier molecule for biosyn-
thesis of mycolylarabinogalactan and trehalose-6,60-dimycolate
(TDM).3 Following the mycolyltransfer reaction, trehalose is trans-
ported from the periplasmic space back into the cytoplasm and
recycled for use in the production of various trehalolipids and
⇑
Corresponding author. Tel.: +1 419 530 1504; fax: +1 419 530 1990.
E-mail address: steve.sucheck@utoledo.edu (S.J. Sucheck).
Scheme 1. The GlgE pathway from trehalose to a-glucan.
0968-0896/$ - see front matter Ó 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmc.2013.12.058

S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
1405
combination of gene essentiality within a synthetic lethal pathway
which substantiates GlgE as a new potential drug target candidate
for the treatment of TB. Since GlgE is the first enzyme involved in
5 in 97% yield.14 The target C-phosphonate 13 would have been ac-
cessed by a Horner–Wadsworth–Emmons9 reaction mediated by
tetramethyl methylenediphosphonate followed by global depro-
tection; however, the major product was the elimination product
7. The initial base used in the HWE was 50% NaOH (aq). As alterna-
tives, we explored LiHMDS, LDA and sodium methoxide however
these alternatives did not mitigate the problem. We also explored
the Lewis acid catalyzed reaction15 of a maltose b-acetate and
a-glucan synthesis suggested to be a potential target for develop-
ing antimicrobials, to date, no inhibitors have been described.
Syson et al. determined the structure of GlgE isoform I from
Streptomyces coelicolor (Sco) which placed GlgE in the glycosylhy-
drolase family GH13_3, which use a double displacement enzy-
matic mechanism consistent with that of the related retaining
glycosyl hydrolases.7 The Syson study demonstrated that Sco GlgE
and Mtb GlgE have similar catalytic properties and suggest that the
Sco GlgE can be used as a surrogate for understanding the Mtb
GlgE.8 GlgE was predicted to bind M1P within the so-called sucrose
phosphorylase +1 subsite and catalysis is proposed to use phos-
propargyltrimethylsilane to afford an
a-C-allenyl maltoside (not
shown). C-allenes can be converted to aldehydes by ozonolysis15
followed by reduction to give alcohols. The alcohols can be trans-
formed to iodides16 and phosphorylated by using trimethyl phos-
phite to afford phosphonates; however, the reaction yields were
modest.
phate as a leaving group. GlgE exhibits an
a-retaining catalytic
mechanism9 forming linear -glucans as shown in Scheme 2.8
a
2.2. Synthesis of maltose-C-phosphonate 13 using Wittig
olefination followed by Michealis–Arbuzov reaction
Based on this information, the authors hypothesized that aspartic
acid 394 and glutamic acid 423 represent key catalytic residues
that function in the enzymatic reaction as the nucleophile and gen-
eral acid, respectively (Sco numbering).
Walker and Vederas have reported the generation of a-C-glyco-
side phosphonates17 via a Wittig olefination followed by an intra-
molecular oxymercuration with introduction of the phosphonate
moiety by a Michaelis–Arbuzov reaction in order to synthesize
mono- and disaccharide analogs of moenomycin and lipid II for
inhibition of the transglycosylase activity of penicillin-binding pro-
tein 1B. Thus, we saw an opportunity to preserve some of Scheme 3
by reacting reducing sugar 5 with the ylide formed from deproto-
nation of methyltriphenylphosphonium bromide with n-butyllith-
ium to produce alkene18 8, Scheme 4. Cyclization of the alkene
with mercury trifluoroacetate followed by anion exchange with
KCl to afforded alkylmercuric chloride 9. Iodo-demercuration med-
iated by iodine afforded the alkyl iodide 10. The primary alkyl
iodide was displaced with trimethyl phosphite using a Michaelis–
Arbuzov reaction17 to afford the phosphonate 11. By global
deprotection of the dimethyl phosphonates with trimethylsilyl
bromide followed by hydrogenolysis using 20% Pd(OH)2 on carbon
under 1 atm hydrogen gas yield the target molecule 13.
Based on the above mechanism, we expected a non-hydrolyz-
able and isosteric analog of M1P, maltose C-phosphonate (MCP)
13 would interact sufficiently with the substrate binding pocket
to produce an inhibitory effect. Such a compound, since it would
be non-hydrolyzable, is expected to have future value in structural
biology studies that could aid inhibitor development. Synthesis of
glycosyl C-phosphonates has been accomplished before for glucose
and ribose monosaccharides. The most common routes for synthe-
sis of such compounds comprise (i) a Horner–Wadsworth–Em-
mons approach that involves treating glycosyl donor 5 with
tetramethyl methylene diphosphate10 or (ii) a Michaelis–Arbuzov
reaction between an anomeric halomethylene moiety and a trialkyl
phosphite. We investigated both synthetic strategies in order to
elaborate maltose into the desired target MCP 13.
2. Results
2.3. Synthesis of maltose-1-phosphate disodium salt 16
2.1. Attempted synthesis of maltose-C-phosphonate 13 (MCP)
using a Horner–Wadsworth–Emmons (HWE) approach
In order to perform inhibition studies, Syson et al. synthesized
the substrate molecule maltose-1-phosphate with acetyl protec-
tion in which they obtained the b-anomer as the major product
In order to synthesize the target molecule, maltose (1) was first
peracetylated with acetic anhydride followed by glycosylation
with allyl alcohol and boron trifluoride diethyl etherate to generate
a peracetylated allyl maltoside,11 Scheme 3.
Subsequently, deacetylation under Zemplén conditions afforded
glycoside 3 followed by benzylation to afford a mixture of perben-
zylated allyl maltoside 412 in 85% yield. To deprotect the anomeric
allyl group, we treated 4 with N-bromosuccinimide.13 Instead of
obtaining the reducing sugar 5 we obtained a bromo-substituted
adduct (not shown) which was confirmed by ESI–MS. As an alter-
native, we treated 4 with palladium chloride in methanol to obtain
and used HPLC to purify out the desired a-anomer. HPLC is a pow-
erful yet tedious process. Thus, to access M1P more readily for fu-
ture assay development we synthesized substrate 16 by treating
compound 5 with tetrabenzyl pyrophosphate to provide phosphate
ester 14 in 56% yield (Scheme 5) with the a-anomer as the princi-
ple product. Purification was performed easily using flash column
chromatography on silica gel. Further, intermediate 14 could be
globally deprotected in a single step with 20% Pd(OH)2 on carbon
under H2 gas. The phosphonic acid was converted to the stable so-
dium salt 16 by treatment with triethylamine followed by cation
Scheme 2. Proposed mechanism of GlgE. The numbering Asp418 and Glu447 are based on the numbering of Mycobacterium tuberculosis GlgE.

1406
S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
Scheme 3. Reagents and conditions: (i) Ac2O, pyridine, cat. DMAP, rt (95%); (ii) BF3-Et2O, allyl alcohol, CH2Cl2, rt; (iii) NaOMe, MeOH, 1 h, rt (90%); (iv) NaH, BnBr, DMF, rt
(85%); (v) PdCl2, MeOH, rt (97%); (vi) CH2[P(O)(OMe)2]2, 50% NaOH, DCM, rt.
Scheme 4. Reagents and conditions: (i) nBuLi, Ph3PCH3Br PPh3 = CH2, dry THF, rt (51%); (ii) (a) Hg(CF3CO2)2; (b) KCl, dry THF, rt (97%); (iii) I2, CH2Cl2, rt (90%); (iv) P(OCH3)3,
reflux, 24 h, rt (86%); (v) TMSBr, CH2Cl2, rt (75%); (vi) 20% Pd(OH)2 on carbon/H2, THF/EtOH, rt, quantitative.
Scheme 5. Reagents and conditions: (i) Tetrabenzyl pyrophosphate, LDA, ꢀ72 to
0 °C, (56%); (ii) (a) 20% Pd(OH)2 on carbon/H2, THF/EtOH, rt; (b) Et3N, rt; (iii) Dowex
Na+ resin, quantitative.
Figure 1. Mtb GlgE coupled enzyme assay utilizing PNP. (a) M1P and glycogen
(n = a number of maltose units) serve as substrates for GlgE. (b) PNP consumes Pi
and MESG to form 2-amino-6-mercapto-7-methyl-purine.
exchange through DowexÒ 50WX8 H+ that had been converted to
the Na+ form.8
2-amino-6-mercapto-7-methyl-purine shifts absorbance from 330
to 360 nm, respectively. The assay is described in Figure 1.
2.4. Mtb GlgE inhibition studies
Using this assay we determined an IC50 for compound 13. As-
says were performed under atmospheric pressure at 22 °C in a 96
well format on a Spectra max 340PC (Molecular Devices). All
1 mM MESG stock solutions were prepared and stored in dH2O at
ꢀ20 °C. Phosphate release, catalyzed by Mtb GlgE, was monitored
by the production of 2-amino-6-mercapto-7-methyl-purine in a
coupled assay catalyzed by purine nucleoside phosphorylase. The
reaction was monitored at 5 s intervals for 30 min. Each reaction
consisted of 1 mM MESG, 0.2 U of PNP, 20X reaction buffer
An EnzChekÒ Phosphate Assay Kit (Molecular Probes) was used
to couple the phosphate produced from Mtb GlgE activity into a
colorimetric readout. The phosphate assay can be performed con-
tinuously as a coupled assay or an endpoint assay and is based
on work originally described by Webb.19 Briefly, purine nucleoside
phosphorylase (PNP) converts the substrate 2-amino-6-mercapto-
7-methylpurine riboside (MESG) to ribose-1-phosphate and 2-ami-
no-6-mercapto-7-methyl-purine (Fig. 1).18 Conversion of MESG to

S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
1407
those ongoing studies are expected to provide valuable insight
concerning the development of more potent Mtb GlgE inhibitors.
4. Conclusion
We have synthesized a substrate analog of maltose-1-phos-
phate the substrate for Mtb GlgE. Key steps in the synthesis of
the target C-phosphonate were the use of a Wittig olefination, an
intramolecular oxymercuration, and a Michealis–Arbuzov reaction
between alkylhalide and a trialkylphosphite. MCP 13 inhibited Mtb
GlgE at IC50 = 230 24
lM. We were also able to synthesize M1P as
the desired -anomer as the exclusive product. The purification of
a
the protected M1P was performed easily. Rapid access to M1P is
critical to our efforts on development high throughput screening
capabilities for identifying inhibitors of Mtb GlgE. The ongoing
crystallization studies of MCP 13 Mtb and Sco GlgE are expected
to provide information that with aid us in the development of
new anti-tuberculosis drugs.
0
Figure 2. IC50 determination of MCP 13. Vo and Vo are steady-state rates with and
without inhibitor. Error bars are calculated from the result of reactions performed
in triplicate.
(1.0 M Tris–HCl, 20 mM MgCl2, pH 7.5, containing 2 mM sodium
azide), 50 nm GlgE, 250 lM M1P (16) and varied concentration of
inhibitor MCP 13. Inhibition was determined by comparing the rel-
5. Experimentals
5.1. Materials
ative rate of the reaction performed with inhibitor against a reac-
0
0
tion that contained no inhibitor (Vo / Vo), where Vo and Vo are
steady-state rates with and without inhibitor, respectively. The
inhibitor concentration that reduced enzyme activity by 50%
All fine chemicals such as D-(+)-maltose monohydrate, benzyl
bromide, methyltriphenylphosphonium bromide, 20% palladium
hydroxide on carbon powder, palladium chloride, trimethyl silylbr-
omide and anhydrous solvents such as anhydrous methanol and
N,N-dimethylformamide were purchased from Acros and used
without further purification. Trimethylphosphite and n-butyl lith-
ium were purchased from Sigma–Aldrich. Tetramethyl methylen-
ediphosphate, tetrabenzyl pyrophosphate and mercury (II)
trifluoroacetate were purchased from Alfa Aesar. Potassium chlo-
ride and all other the solvents were obtained from Fisher. Silica
(230–400 mesh) for column chromatography was obtained from
Sorbent Technologies; Thin-layer chromatography (TLC) precoated
plates were from EMD. TLCs (silica gel 60, f254) were visualized un-
der UV light or by charring (5% H2SO4–MeOH). Flash column chro-
matography was performed on silica gel (230–400 mesh) using
solvents as received. 1H NMR were recorded either on INOVA
600 MHz spectrometer in CDCl3 using residual CHCl3 and TMS as
internal references, respectively. 13C NMR were recorded on the
VXRS 400, INOVA 600 and AVANCE 600 in CDCl3 using the triplet
centered at d 77.27 as internal reference. High resolution mass
spectrometry (HRMS) was performed on a micro mass Q-TOF2
instrument. EnzChekÒ Phosphate Assay Kit was purchased from
Molecular Probes for use in the Mtb GlgE inhibition assay.
(IC50) was found from the graph (Fig. 2) to be 230
lue is near the reported Mtb GlgE Km of 250
l
M
24. This va-
l
M
5.8
3. Discussion
Mtb GlgE is considered a validated target for killing Mtb. We
initiated efforts to develop a carbohydrate-based substrate analog
of M1P, the substrate of the enzyme. We anticipated that
maltose-C-phosphonate 13 would be isosteric and isoelectronic
with M1P; however, it would also be non-hydrolyzable and would
therefore inhibit GlgE. We were able to access the phosphonate
inhibitor by subjecting the C1 halomethylene to a Michealis–
Arbuzov reaction using a trialkylphosphite. Coupling constants
for the C1⁄ methylene protons maltose-C-phosphonate 13 were
at
d 2.18 ppm (ddd, J1⁄a, 1⁄b = 15.87 Hz, J1⁄a,1 = 11.72 Hz, J1⁄a,
P = 27.34 Hz) for H1⁄a, 2.00 ppm (ddd, J1⁄a, 1⁄b = 15.87 Hz,
J1⁄b,1 = 5.08 Hz, J1⁄b, P = 19.78 Hz) for H1⁄b protons. In comparison
to literature20 which is reported for a galactose C-phosphonate
the
a-anomer possessed resonances at 2.06 ppm (ABXX’, J1⁄a,
1⁄b = 15.6 Hz, J1⁄a,1 = 10.7 Hz, J1⁄a, P = 26.5 Hz) for H1⁄a, and
1.93 ppm (ABXX0, J1⁄b,1 = 4.0 Hz, J1⁄b, P = 19.6 Hz, J1⁄a, 1⁄b = 15.6 Hz)
5.2. Synthesis
for H1⁄b. The
a
-anomer possessed resonances at 2.17 ppm (ABXX0,
J1⁄a,1 = 2.8 Hz, J1⁄a, P = 19.0 Hz, J1⁄a, 1⁄b = 15.4 Hz) for H1⁄a, and
1.82 ppm (ABXX’. J1⁄b,1 = 9.4 Hz, J1⁄b, P = 21.9 Hz, J1⁄a, 1⁄b = 15.4 Hz)
for H1⁄b. Comparing the coupling constant of J1⁄a,1 for the three
5.2.1. 1,2,3,6,20,30,40,60-octa-O-acetyl-
-(+)-Maltose monohydrate (1.00 g, 2.78 mmol) was suspended
D
-maltose (2)21
D
in dry pyridine (3.60 mL, 44.5 mmol) and acetic anhydride
(3.14 mL, 33.4 mmol) and a catalytic amount of 4-dimethylamino-
pyridine was added. The solution was stirred at ambient tempera-
ture for 16 h. The reaction mixture was diluted with ethyl acetate
and washed successively with 1 N HCl (10 mL) and saturated aq
NaHCO3 (20 mL). The resulting organic phase was dried (anhy-
drous Na2SO4), filtered and the filtrate concentrated under reduced
pressure; yield: 95% (1.79 g); silica gel TLC Rf = 0.5 (1:1 acetone–
hexanes).
compounds strongly supports the assignment of the
a-anomer.
We attempted to evaluate the inhibitory activity of maltose-C-
phosphonate against Mtb GlgE using a malachite green-base assay6
but encountered elevated background levels that hindered data
analysis. Therefore, we moved on to a PNP-based coupled enzyme
assay. The PNP coupled assay was simple to operate and exhibited
a clear inhibitor concentration dependent decrease in enzymatic
activity; furthermore, it has the potential to be performed in a con-
tinuous mode. We could synthesize M1P 16 easily from intermedi-
ate 5 without the need of HPLC purification. The a-anomer was the
5.2.2. Allyl 4-O-a-D-glucopyranosyl-a/b-D
-glucopyranose11 (3)
Peracetylated maltose 2 (500 mg, 0.74 mmol) was dissolved in
dichloromethane. Allyl alcohol (0.16 mL, 2.22 mmol) and boron tri-
fluoride diethyl etherate (0.28 mL, 2.22 mmol) were added to the
principle product and had having spectroscopic properties identi-
cal to those reported in literature.8 We are currently in the process
of addressing the detailed mode of interaction of MCP 13 with Mtb
GlgE and Sco GlgE via co-crystallization studies. The data from

1408
S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
solution at 0 °C. The resulting solution was stirred at ambient tem-
perature under nitrogen atmosphere. The reaction was monitored
by TLC and appeared to be complete after 4 h. The reaction mixture
was diluted with dichloromethane (7 mL) and successively washed
with saturated aq NaHCO3 (8 mL), 10% aq NaCl (4 mL), and water
(8 mL). The resulting organic phase was dried (anhydrous Na2SO4),
filtered and the filtrate was concentrated under reduced pressure.
The product was dried overnight and deacetylated by dissolving in
dry methanol followed by addition of a catalytic amount of sodium
metal until the solution reached pH 9. The reaction was monitored
for completion using TLC. The reaction was neutralized by adding
Amberlite IRA-118H H+ resin until the pH reached 7. Then resin
was filtered away and the filtrate concentrated under reduced
pressure to afford the allyl maltoside 3; yield: 90% (0.45 g).
reduced pressure to obtain the crude product. The product was
purified by silica gel flash column chromatography by eluting with
9:1 hexanes–ethyl acetate. The product fractions were combined,
concentrated, and dried in vacuum to afford a yellow oil; yield:
51.3% (0.33 g); silica gel TLC Rf = 0.63 (3:7 ethyl acetate–hexanes);
½
a 2D3 58.4° (c 0.5, CHCl3); 1H NMR (CDCl3, 600 MHz): d 3.52 (m, 3H,
ꢁ
H-6b, H-6b0, H-20), 3.64(m, 2H, H-6a, H-40), 3.76 (dd, 1H, J = 4.2,
5.4 Hz, H-3), 3.92(t, 1H, J = 4.8 Hz, H-4), 3.95 (t, 1H, J = 9 Hz,
H-30), 4.02 (m, 1H, H-50), 4.12 (m, 1H, H-5), 4.28 (dd, 1H, J = 6,
12 Hz, H-2), 4.92–4.38 (m, 14H, –CH2Ph), 4.96 (d, 1H, J = 3.6 Hz,
H-1), 5.22 (dd, 2H, J = 17.4, 29.4 Hz, @CH2), 5.91 (m, 1H, H-10),
7.32–7.09 (m, 35H, Aromatic H0s); 13C NMR (150 MHz, CDCl3): d
68.54, 70.77, 71.18, 71.55, 71.60, 73.39, 73.51, 73.66, 74.31,
75.21, 75.70, 78.03, 79.32, 80.60, 81.63, 82.13, 99.12, 118.86,
127.69, 127.73 (2 C0s), 127.76 (2 C0s), 127.82 (2 C0s), 127.83 (2
C0s), 127.85 (2 C0s), 127.86 (2 C0s), 127.87 (2 C0s), 128.04 (2 C0s),
128.05 (2 C0s), 128.08 (2 C0s), 128.19 (2 C0s), 128.36 (2 C0s),
128.51 (2 C0s), 128.52 (2 C0s), 128.53 (2 C0s), 128.57 (2 C0s),
135.74 (2 C0s), 138.12 (2 C0s), 138.35 (2 C0s), 138.41 (2 C0s),
138.48, 138.52, 138.93 ppm; mass spectrum (HRMS), m/
z = 993.4581 (M+Na)+, C61H64O11 requires 993.4554.
5.2.3. Allyl2,3,6-Tri-O-benzyl-4-O-(20,30,40,60-tetra-O-benzyl-
glucopyranosyl)- /b-
-glucopyranoside (4)12
A solution of allyl 4-O- -glucopyranosyl-a/b-D-glucopyranose
a-D-
a
D
a-D
(3) (840 mg, 2.19 mmol) in dry N,N-dimethylformamide (40 mL)
was cooled to 0 °C. The solution was treated drop-wise with a sus-
pension of sodium hydride (60% dispersion in mineral oil) (1.073 g,
26.82 mmol) in dry N,N-dimethylformamide. Benzyl bromide
(2.73 mL, 23.0 mmol) was added drop-wise over 15 min and the
solution stirred at room temperature for 16 h. The reaction was
poured over ice and extracted with diethyl ether (20 mL). The com-
bined organic layers were washed with brine. The resulting organic
phase was dried (anhydrous Na2SO4), filtered and the filtrate con-
centrated under reduced pressure to obtain a product. The product
was purified by silica gel flash column chromatography by eluting
with 9:1 hexanes–ethyl acetate. The product fractions were com-
bined, concentrated, and dried in vacuum to afford a yellow oily
product; yield: 85% (1.87 g); silica gel TLC Rf = 0.61 (8:2 hexanes–
ethyl acetate).
5.2.6. 2,3,6,20,30,40,60-Hepta-O-benzyl-
a-D-maltosyl methyl
mercuric chloride (9)
A solution of 3,4,7-tri-O-benyl-5-O-(20,30,40,60-tetra-O-benzyl-
a-
D-glucopyranosyl)-D-glucphept-1-enitol (8) (0.3 g, 0.3 mmol) and
mercuric trifluoroacetate (0.1 g, 0.3 mmol) in dry tetrahydrofuran
(21 mL) was stirred at room temperature for 3 h. A solution of
potassium chloride (0.179 g) in 3 mL of water was added and the
mixture was stirred for another 3 h. The tetrahydrofuran was re-
moved under reduced pressure and the remaining aqueous solu-
tion was extracted with dichloromethane. The combined extracts
were washed with brine, dried (anhydrous MgSO4), filtered and
the filtrate was concentrated under reduced pressure to obtain
the crude material. The crude material was purified by silica gel
flash column chromatography eluting with 9:1 hexanes–ethyl ace-
tate. The product fractions were combined, concentrated, and dried
in vacuum to afford yellow oily liquid; yield: 97% (0.35 g); silica gel
5.2.4. 2,3,6-Tri-O-benzyl-4-O-(20,30,40,60-tetra-O-benzyl-
glucopyranosyl)- /b-
-glucopyranoside (5)12
Allyl 2,3,6-tri-O-benzyl-4-O-(20,30,40,60-tetra-O-benzyl-
copyranosyl)- /b- -glucopyranoside (4) (0.4 g, 0.4 mmol) and pal-
a-D-
a
D
a-D-glu-
a
D
ladium (II) chloride (0.2 mg, 0.6 mmol) in dry methanol (16 mL)
were stirred vigorously for overnight at ambient temperature until
consumption of starting material was observed by TLC. The reac-
tion was diluted with diethyl ether, filtered through Celite™ 545
filter aid and concentrated under reduced pressure to obtain the
crude product. The crude product was purified by silica gel flash
column chromatography using 9:1 hexanes–ethyl acetate. The
product fractions were combined, concentrated, and dried under
reduced pressure to afford a colorless glassy solid; yield: 97%
(0.384 g); silica gel TLC Rf = 0.19 (3:7 ethyl acetate–hexanes).
TLC Rf = 0.45 (3:7 ethyl acetate–hexanes); ½a D23
ꢁ
= 27.6° (c 0.5,
CHCl3); 1H NMR (CDCl3, 600 MHz): d 1.83 (dd, 1H, J = 6, 12 Hz,
H1⁄a), 2.06 (dd, 1H, J = 9, 11.4 Hz, H1⁄b), 3.46 (dd, 1H, J = 1.2,
10.2 Hz, H-40), 3.51 (dd, 1H, J = 3.6, 9.6 Hz, H-20), 3.61 (dd, 1H,
J = 3, 8.4 Hz, H-2), 3.64 (m, 2H, H-6b, H-6b0), 3.71 (dd, 1H, J = 5.4,
10.8 Hz, H-3), 3.76 (m, 1H, H-50), 3.98 (m, 1H, H-6a), 3.94 (m, 2H,
H-6a, H-6a0), 3.94 (m, 1H, H-5), 4.18 (m, 1H, H-1), 4.85–4.37 (m,
14H, –CH2Ph), 5.40 (d, J = 3.6 Hz, H-10), 7.32–7.39 (m, 35H, Aro-
matic H0s); 13C NMR (150 MHz, CDCl3): d 68.35, 69.33, 71.31,
71.47, 71.92, 73.38, 73.65, 73.71, 73.78, 73.97, 75.15, 75.73,
76.91, 77.94 (2 C0s), 79.63, 80.08, 82.12, 97.62, 127.03 (2 C0s),
127.66 (2 C0s), 127.71 (2 C0s), 127.73 (2 C0s), 127.79 (2 C0s),
127.84 (2 C0s), 127.88 (2 C0s), 127.91 (2 C0s), 127.99 (2 C0s),
128.02 (2 C0s), 128.23 (2 C0s), 128.47 (2 C0s), 128.51 (2 C0s),
128.54 (2 C0s), 128.59 (2 C0s), 128.86 (2 C0s), 128.92 (2 C0s),
137.26, 138.03, 138.15, 138.19, 138.42, 138.57, 138.85 ppm; mass
spectrum (HRMS), m/z = 1229.3959 (M+H)+, C62H65ClHgO10 re-
quires 1229.3870.
5.2.5. 3,4,7-Tri-O-benyl-5-O-(20,30,40,60-tetra-O-benzyl-
glucopyranosyl)- -glucphept-1-enitol (8)
a-D-
D
2.22 M n-Butyl lithium in hexanes (1.5 mL, 3.3 mmol) was
added drop-wise to a suspension of methyltriphenylphosphonium
bromide (0.95 g, 2.67 mmol) in tetrahydrofuran (14 mL) at ꢀ20 °C.
The solution was stirred at ꢀ20 °C for 15 min and raised to ambient
temperature for 1 h. The solution was cooled to ꢀ20 °C and 2,3,6-
tri-O-benzyl-4-O-(20,30,40,60-tetra-O-benzyl-
a-D-glucopyranosyl)-
a/b-D
-glucopyranoside (5) (0.65 g, 0.67 mmol) in 13 mL of tetrahy-
5.2.7. 2,3,6,20,30,40,60-Hepta-O-benzyl-
a-
D-maltosyl methyl
drofuran was added drop-wise. The solution was stirred at ꢀ20 °C
for 15 min and allowed to warm to ambient temperature and stir-
red for 6 h. The solution was diluted with acetone (6 mL) and stir-
red for 30 min. Diethyl ether (22 mL) was added to precipitate of
triphenylphosphine oxide. The latter was removed by filtration
through Celite™ 545 filter aid. The filtrate was washed succes-
sively with saturated aq NaHCO3 and brine. The solution was dried
(anhydrous Na2SO4), filtered and filtrate concentrated under
iodide (10)
A
solution of 2,3,6,20,30,40,60-hepta-O-benzyl-
a-D-maltosyl
methyl mercuric chloride (9) (0.32 g, 0.26 mmol) in dry dichloro-
methane (20 mL) was treated with iodine (0.21 g, 0.81 mmol).
After stirring for 1 h the reaction was quenched by addition of so-
dium thiosulfate (500 mg in 6 mL water) and the mixture was stir-
red until the solution became colorless. The organic phase was
separated and washed with water (5 mL), brine (5 mL), dried

S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
1409
(anhydrous MgSO4) and filtered. The filtrate was evaporated under
reduced pressure and purified by silica gel flash column chroma-
tography eluting with 9:1 hexanes–ethyl acetate. The product frac-
tions were combined, concentrated, and dried in vacuum to afford
yellow oily liquid; yield: 89.5% (0.255 g); silica gel TLC Rf = 0.7 (3:7
(150 MHz, CDCl3): d 68.22, 71.02, 71.54, 72.57, 73.46, 73.62,
73.69, 73.74, 75.19, 75.71, 77.75, 79.37, 81.98, 97.68, 125.51 (2
C0s), 126.96 (2 C0s), 127.63 (2 C0s), 127.77 (2 C0s), 127.91 (2 C0s),
127.98 (2 C0s), 128.04 (2 C0s), 128.12 (2 C0s), 128.20 (2 C0s),
128.24 (2 C0s), 128.33 (2 C0s), 128.44 (2 C0s), 128.51 (2 C0s),
128.57 (2 C0s), 128.61 (2 C0s), 128.75 (2 C0s), 129.25(2 C0s),
137.62, 137.97, 138.46, 138.78; 31P NMR (162 MHz, CDCl3): d
30.89 ppm; mass spectrum (HRMS), m/z = 1073.4192 (M+H)+,
ethyl acetate–hexanes); ½a D23
ꢁ
= 37.1° (c 0.5, CHCl3); 1H NMR (CDCl3,
600 MHz): d 3.38 (m, 2H, H-6a, H1⁄a), 3.52 (m, 4H, H-6b, H-6b0, H-
20, H1⁄b), 3.65 (t, 1H, J = 9.6 Hz, H-4), 3.71 (dd, 1H, J = 2.4, 10.8 Hz,
H-3), 3.76 (m, 1H, H-50), 3.81 (dd, 1H, J = 4.2, 10.8 Hz, H-2), 3.84 (m,
1H, H-5), 3.89 (dd, 1H, J = 3, 9.6 Hz, H- 30), 4.01 (dd, 1H, J = 6, 9 Hz,
H-40), 4.16 (m, 1H, H-1), 4.84–4.28 (m, 14H, –CH2Ph), 5.41 (d,
J = 3.6 Hz, 1H), 7.32–7.09 (m, 35H, Aromatic H0s); 13C NMR
(150 MHz, CDCl3): d 68.22, 69.69, 71.18, 71.90, 72.97, 73.40,
73.44, 73.50, 73.62, 73.71, 73.73, 75.14, 75.70, 77.81, 77.86,
79.63, 79.91, 82.14, 97.25, 127.14 (2 C0s), 127.55 (2 C0s), 127.67
(2 C0s), 127.73 (2 C0s), 127.80 (2 C0s), 127.87 (2 C0s), 127.91 (2
C0s), 127.96 (2 C0s), 128.00 (2 C0s), 128.07 (2 C0s), 128.09 (2 C0s),
128.10 (2 C0s), 128.23 (2 C0s), 128.42 (2 C0s), 128.48 (2 C0s),
128.52 (2 C0s), 128.56 (2 C0s), 128.59 (2 C0s), 128.63 (2 C0s),
137.86, 138.04, 138.14, 138.47, 138.53, 138.55, 138.88 ppm; mass
spectrum (HRMS), m/z = 1119.3505 (M+H)+, C62H65IO10 requires
1119.3520.
C62H67O13P requires 1073.4217.
5.2.10.
Palladium hydroxide (10%) on carbon (catalytic amount) was
added to a solution of 2,3,6,20,30,40,60-Hepta-O-benzyl-
-malto-
a-D-Maltose C-phosphonate (13)
a
-D
syl)methylphosphonic acid (12) (90.0 mg, 0.08 mmol) in tetrahy-
drofuran (0.2 mL) and ethanol (1.8 mL), The reaction mixture was
stirred at ambient temperature under hydrogen atmosphere over-
night. The catalyst was filtered away and washed with 20% meth-
anol/dichloromethane and methanol. The filtrate was concentrated
to dryness to afford maltose-C-phosphonate (13); yield: 100%
(35 g);½a 2D3
ꢁ
81.5° (c 1, H2O); 1H NMR (CDCl3, 600 MHz): d 2.00
(ddd, 1H, J1⁄a, 1⁄b = 15.87 Hz, J1⁄b, 1 = 5.08 Hz, J1⁄b, P = 19.78 Hz,
H1⁄b), 2.18 (ddd, 1H, J1⁄a, 1⁄b = 15.87 Hz, J1⁄a,1 = 11.72 Hz, J1⁄a,
P = 27.34 Hz, H1⁄a), 3.35 (t, 1H, J = 9.6 Hz, H-40), 3.52 (dd, 1H,
J = 7.2 Hz, 10.8 Hz,H-20), 3.80 (m, 5H, H-6a,b, H-5, H-2, H-30, H-4),
4.32 (m, 1H, H-1), 5.15 (d, 1H, J = 6 Hz); 13C NMR (150 MHz, CDCl3):
d 24.62, 60.23, 60.32, 69.22, 70.39, 70.48, 70.85, 71.58, 72.02, 72.47,
72.75, 76.54, 99.34. 31P NMR (162 MHz, CDCl3): d 26.34 ppm; mass
spectrum (HRMS), m/z = 443.0930 (M+H)+, C13H25O13P requires
443.0942.
5.2.8. Dimethyl (2,3,6,20,30,40,60-Hepta-O-benzyl-
a-D-
maltosyl)methylphosphonate (11)
Trimethyl phosphite (7 mL) was added to 2,3,6,20,30,40,60-hepta-
O-benzyl-a-D-maltosyl methyl iodide (0.24 g, 0.22 mmol) and the
solution was refluxed for 24 h. The resulting solution was concen-
trated at 35 °C under reduced pressure to get the crude material.
The crude material was purified by silica gel flash column chroma-
tography eluting with 1:1 hexanes–ethyl acetate. The product frac-
tions were combined, concentrated, and dried in vacuum to afford
yellow oily liquid; yield: 86% (0.20 g); silica gel TLC Rf = 0.2 (1:1
5.2.11. Dimethyl 3,7-di-O-benyl-5-O-(20,30,40,60-tetra-O-benzyl-
a
-
D
-glucopyranosyl)-
A 50% aq solution of NaOH (2 mL) was slowly added to a vigor-
ously stirring mixture of 2,3,6-tri-O-benzyl-4-O-(20,30,40,60-tetra-O-
benzyl- -glucopyranosyl)- /b- -glucopyranoside (5) (40.0 mg,
D-glucphept-1,3-dienitol phosphonate (7)
ethyl acetate–hexanes); ½a D23
ꢁ
= 30.8° (c 1, CHCl3); 1H NMR (CDCl3,
600 MHz): d 2.18 (m, 1H, H1⁄a), 2.28 (m, 1H, H1⁄b), 3.42 (dd,
1H, J = 1.2, 10.2 Hz, H-4), 3.51 (dd, 1H, J = 3.6, 10.2, H-20), 3.55
(dd, 1H, J = 3, 10.8 Hz, H-3), 3.65 (dd, 1H, J = 3, 8.4 Hz, H-40), 3.69
(t, J = 10.8 Hz, –OCH3), 3.79 (m, 3H, H-5, H-50, H-2), 3.91 (t, 1H,
J = 9.6 Hz, H-30), 4.86–4.28 (m, 14H, –CH2Ph), 5.54 (d, 1H,
J = 3.6 Hz, H-10), 7.32–7.09 (m, 35H, Aromatic H0s); 13C NMR
(150 MHz, CDCl3): d 52.61, 52.66, 68.27, 68.93, 68.96, 69.35,
71.16, 72.14, 72.86, 73.08, 73.42, 73.59, 73.66, 73.72, 75.15,
75.72, 77.02, 77.23, 77.44, 77.84, 78.71, 79.64, 80.67, 82.18,
97.27, 127.03(2 C0s), 127.53 (2 C0s), 127.61 (2 C0s), 127.67 (2 C0s),
127.72 (2 C0s), 127.80 (2 C0s), 127.85 (2 C0s), 127.88 (2 C0s),
127.99 (2 C0s), 128.02 (2 C0s), 128.13 (2 C0s), 128.26 (2 C0s),
128.42 (2 C0s), 128.49 (2 C0s), 128.53 (2 C0s), 128.61 (2 C0s),
137.87, 138.08, 138.17, 138.46, 138.62, 138.66, 138.93 ppm; 31P
NMR (162 MHz, CDCl3): d 33.19 ppm; mass spectrum (HRMS),
m/z = 1101.4530 (M+H)+, C64H71O13P requires 1101.4507.
a
-D
a
D
0.04 mmol) and tetramethyl methylenediphosphonate (10.4 mg,
0.04 mmol) in dichloromethane (2 mL). After 18 h of stirring at
ambient temperature the reaction was complete. The reaction
was diluted with dichloromethane and the aqueous phase was ex-
tracted with dichloromethane. The combined organic phases were
dried (anhydrous MgSO4), filtered and the filtrate concentrated un-
der reduced pressure to get the crude material. The crude material
was purified by silica gel flash column chromatography eluting
with 9:1 hexanes–ethyl acetate. The product fractions were com-
bined, concentrated, and dried in vacuum to afford yellow oily li-
quid; yield: 45% (20 mg); silica gel TLC Rf = 0.7 (1:9 ethyl
acetate–hexanes); 1H NMR (CDCl3, 600 MHz): d 3.63–3.52 (m,
4H, H0-5, H0-4, H0-6a,b), 3.72 (m, 6H, –OCH3), 3.88 (t, 1H,
J = 9.6 Hz, H0-3), 4.231 (d, 1H, J = 12 Hz, H-3), 4.46 (dd, 1H,
J = 2.4 Hz, 9.6 Hz, H-4), 4.69–4.74 (m, 4H, H-2, H-5, H-6a,b), 4.94–
4.76 (m, 12H, –CH2Ph), 5.948 (dd, 1H, J = 3.6 Hz, 13.8 Hz, H-1),
6.949 (dd, 1H, J = 4.8 Hz, 16.8 Hz, H-2), 7.34–6.98 (m, 30H,aromatic
H0s); 13C NMR (150 MHz, CDCl3): d 20.93, 21.92, 55.65, 68.98,
71.45, 75.96, 78.85, 80.77, 81.16, 81.12, 107.04, 128.19, 128.25,
128.32, 130.17, 130.16, 133.01, 145.26, 170.17, 170.53,
170.74 ppm; 31P NMR (162 MHz, CDCl3): d 23.69 ppm; mass spec-
trum (ESIMS), m/z = 993.7 (M+Na)+, C57H63O12P requires 970.41.
5.2.9. (2,3,6,20,30,40,60-Hepta-O-benzyl-
maltosyl)methylphosphonic acid (12)
Bromotrimethylsilane (0.4 mL, 2.8 mmol) was added to a solu-
tion of dimethyl 2,3,6,20,30,40,60-hepta-O-benzyl-
-maltosyl
a-D-
a-D
phosphonate (11) in dichloromethane (3 mL) and stirred at ambi-
ent temperature for 1.5 h. A solution of methanol–water (1:1,
1.8 mL) was added to the reaction and the resulting solution was
concentrated under reduced pressure to dryness to afford phos-
phonic acid 12; yield: 75% (0.147 g); silica gel TLC Rf = 0.16 (1:3
5.2.12. Dibenzyl 2,3,6,20,30,40,60hepta-O-benzyl-
a-D-maltosyl
phosphate (14)
ethyl acetate–hexanes); ½a D23
ꢁ
= 26.8° (c 1, CHCl3); 1H NMR (CDCl3,
2.22 M n-Butyl lithium in hexanes (0.63 mL, 1.39 mmol) was
added drop-wise to a suspension of diisopropyl amine (0.19 mL,
1.39 mmol) in tetrahydrofuran (6 mL) at ꢀ78 °C. The solution
was stirred and warmed to 0 °C in 15 min. 2,3,6-tri-O-benzyl-4-
600 MHz): d 2.12 (m, 1H, H1⁄a), 2.44 (m, H1⁄b), 3.31 (d, 1H,
J = 10.2 Hz, H-4), 3.51 (m, 4H, H-40, H-6b,H-6b0, H-20), 3.71 (m,
1H, H-50), 3.77 (t, 1H, J = 8.4 Hz, H-2), 3.82 (t, J = 7.2 Hz, H-30),
3.92 (t, J = 7.8 Hz, H-3), 4.78–4.32 (m, 15H, –CH2Ph, H-1), 5.36 (d,
1H, J = 3 Hz, H-10), 7.32–7.09 (m, 35H, Aromatic H0s); 13C NMR
O-(20,30,40,60-tetra-O-benzyl-
a
-
D
-glucopyranosyl)-
a/b-D-glucopy-
ranoside (0.8 g, 0.8 mmol) in tetrahydrofuran (12 mL) was added

1410
S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
slowly and cooled to ꢀ80 °C under nitrogen atmosphere. After
10 min stirring a solution of tetrabenzyl pyrophosphate (0.66 g,
1.23 mmol) in tetrahydrofuran (6 mL) was added and stirred con-
tinuously before being warm to +4 °C followed by stirring for
16 h. An off-white precipitate of LiOP(O)(OBn)2 was removed by
filtration. The resulting solution was evaporated to dryness under
reduced pressure and the product was re-dissolved in ethyl ace-
tate. The organic layer was washed successively with saturated
aq. NaHCO3 and brine. The solution was dried (anhydrous Na2SO4),
filtered and filtrate concentrated under reduced pressure to obtain
the crude product. The crude product was purified by silica gel
flash chromatography eluting with 1:9 ethyl acetate–toluene. The
product fraction were combined, concentrated, and dried in vac-
uum to afford yellow oily liquid; yield: 30% (0.3 g); silica gel TLC
prior to lysis by sonication. The resulting suspension was centri-
fuged at 15,000g for 30 min. The supernatant was applied to a
5 mL HiTrap Talon Crude column (GE Healthcare) previously
equilibrated with buffer A. Proteins were eluted from the column
by applying a linear gradient of imidizole from 5–500 mM over
20 column volumes. Fractions containing GlgE were pooled and ap-
plied to a Hi-Load Superdex 200 size exclusion column for further
purification. GlgE was eluted from the column isocratically with a
buffer containing 150 mM NaCl, 20 mM Tris pH 7.5, and 0.3 mM
TCEP. Fractions containing only GlgE were subsequently pooled.
The purity of the protein was confirmed using SDS–PAGE and
concentrated to 5.28 mg/mL.
7. Inhibition studies
Rf = 0.6 (3:7 ethyl acetate–toluene); ½a D23
ꢁ
= 42.7° (c 1, CHCl3); 1H
NMR (CDCl3, 600 MHz): d 3.37 (d, 1H, J = 10.2 Hz, H-3), 3.49
(m,3H, H0-2, H0-5, H0-4), 3.67 (m, 3H, H0-4, H0-6a,b, H-2), 3.77 (dd,
1H, J1,2 = 3 Hz, J = 11.4 Hz, H-5), 3.89 (t, 1H, J = 9.0 Hz, H-3), 4.02
(m, 2H, H-6a,b), 5.07–4.24 (m, 18H, –CH2Ph), 5.69 (d, 1H,
J = 3 Hz, H0-1), 5.98 (dd, 1H, J = 3 Hz, 6 Hz, H-1), 7.27–7.07 (m,
45H, Aromatic H0s); 13C NMR (150 MHz, CDCl3): d 68.24, 68.44,
69.22, 69.26, 69.41, 71.16, 72.28, 73.06, 73.37, 73.57, 74.06,
75.07, 75.62, 77.74, 79.47, 81.24, 82.03, 95.32, 97.14, 125.39(2
C0s), 126.67(2 C0s), 126.78(2 C0s), 127.45(2 C0s), 127.86(2 C0s),
127.87(2 C0s), 127.88(2 C0s), 128.61(2 C0s), 128.69(2 C0s), 129.12(2
C0s), 135.84, 135.89, 137.43, 138.19, 138.82 ppm; 31P NMR
Assays were performed under atmospheric pressure at 22 °C in
a 96 well format on a Spectra max 340PC (Molecular Devices). All
1 mM MESG stock solutions were prepared and stored in deionized
H2O at ꢀ20 °C. Phosphate release catalyzed by Mtb GlgE was mon-
itored using a coupled assay utilizing purine nucleoside phosphor-
ylase at 5 s intervals for 30 min. For each reaction, a master mix
was made consisting of 1 mM MESG (20
20X reaction buffer (1.0 M Tris–HCl, 20 mM MgCl2, pH 7.5, contain-
ing 2 mM sodium azide) (5 L), 50 nm GlgE (5 L), 250 M M1P
(16)(3.125 L), 40 mM stock solution of inhibitor MCP (13) was
lL), 0.2 U of PNP (1 lL),
l
l
l
l
made in deionized H2O and was added for each corresponding
stock solution to reach the desired inhibitor concentration
(162 MHz, CDCl3):
d
0.90 ppm; mass spectrum (HRMS),
m/z = 1255.484 (M+Na)+, C75H77O14P requires 1232.484.
(31.25–500
lM) and varied volumes of deionized H2O for an over-
all reaction volume of 100
l
L. Inhibitor MCP 13 was not added to
5.2.13.
Palladium hydroxide (10%) on carbon (catalytic amount) was
added to a solution of dibenzyl 2,3,6,20,30,40,60-hepta-O-benzyl-
-maltosyl phosphate (0.27 g, 0.21 mmol) in tetrahydrofuran
(0.6 mL) and ethanol (5.4 mL). The reaction mixture was stirred
at ambient temperature under hydrogen atmosphere overnight.
The catalyst was filtered away and washed with 20% methanol/
dichloromethane and methanol. Ten drops of triethylamine were
added to the filtrate followed by concentration under reduced
pressure to afford a colorless triethylamine salt. The triethylamine
salt was dissolved in water and eluted through DowexÒ 50WX8 H+
that had been converted to the Na+ form. The filtrate containing the
product was concentrated under reduced pressure to afford color-
a-D
-Maltose-1-phosphate, disodium salt8 (16)
the positive control and the negative control lacked GlgE. Inhibi-
tion was determined by comparing the relative rate of the reaction
performed with inhibitor against a reaction that contained no
inhibitor (V0o/Vo), where Vo0 and Vo are steady-state rates with and
without inhibitor, respectively. The inhibitory concentration
(IC50) was obtained by fitting the data into the equation below
using Microsoft Excel:
a
-
D
V00
V0
A2 ꢀ A1
¼ A1 þ
50ꢀlog½IꢁÞP
1 þ 10ðlogIC
A1 is the V0o/Vo value of the bottom plateau of the curve; A2 is the
V0o/Vo value of the top plateau of the curve; [I] and P are inhibitor
concentration and hill slope, respectively.
less a-D-maltose-1-phosphate, disodium salt; yield: 100% (92 mg);
mass spectrum (ESI–MS), m/z = 421.1(MꢀH)ꢀ, C12H21Na2O14P re-
Acknowledgments
quires 466.2.
This work was supported in part by a DeArce Memorial Fund
Grant to S.J.S. from the University of Toledo and a Grant from the
National Institutes of Health (Grant number AI105084) to S.J.S
and D.R.R. We thank Max O. Funk and Ronald E. Viola for their
helpful advice on enzyme kinetics.
6. Protein expression and purification
The glgE (Rv1327c) gene from M. tuberculosis strain H37Rv was
PCR amplified using the following primers: 50-CAC CAT ATG AGT
GGC CGG GCA AT-30 and 50-AAA GGA TCC TCA CCT GCG CAG CA-30.
The product was placed between the NdeI and BamHI cut sites
of a modified pET-28 plasmid. The resulting pDR28-glgE encodes a
recombinant GlgE enzyme possessing an N-terminal polyhistidine
tag. The sequence of the glgE expression plasmid was confirmed by
DNA sequencing.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmc.2013.12.058.
The pDR28-glgE plasmid was used to transform T7 Rosetta cells.
The bacterial cells were cultured at 37 °C in Luria Broth to an O.D.
of 1.2–1.6 at 600 nm. Protein expression was induced by the addi-
tion of IPTG to a final concentration of 1 mM. Cells were harvested
by centrifugation after incubating for 24 h at 16 °C. Pelleted cells
References and notes
1. World Health Organization The Global Tuberculosis Report: 2012, Geneva; World
Health Organization, 2012.
2. Konstantinos, A. Aust. Prescriber 2010, 33, 12.
3. Grzegorzewicz, A. E.; Pham, H.; Gundi, V. A.; Scherman, M. S.; North, E. J.; Hess,
T.; Jones, V.; Gruppo, V.; Born, S. E.; Korduláková, J. Nat. Chem. Biol. 2012, 8, 334.
4. Hatzios, S. K.; Bertozzi, C. R. PLoS Pathog. 2011, 7, e1002036.
5. Kalscheuer, R.; Syson, K.; Veeraraghavan, U.; Weinrick, B.; Biermann, K. E.; Liu,
Z.; Sacchettini, J. C.; Besra, G.; Bornemann, S.; Jacobs, W. R., Jr Nat. Chem. Biol.
2010, 6, 376.
were re-suspended in buffer
500 mM NaCl, 20 mM Tris pH 7.5, 10% glycerol, and 5 mM
b-mercaptoethanol. Lysozyme (10 M) and DNaseI (100 M) were
added to the cell re-suspension and incubated for one hour on ice
A containing 5 mM imidazole,
l
l

S. K. Veleti et al. / Bioorg. Med. Chem. 22 (2014) 1404–1411
1411
6. Kalscheuer, R.; Weinrick, B.; Veeraraghavan, U.; Besra, G. S.; Jacobs, W. R., Jr.
Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 21761.
7. Mc Carter, J. D.; Withers, S. G Curr. Opin. Struct. Biol. 1994, 4, 885.
8. Syson, K.; Stevenson, C. E.; Rejzek, M.; Fairhurst, S. A.; Nair, A.; Bruton, C. J.;
Field, R. A.; Chater, K. F.; Lawson, D. M.; Bornemann, S. J. Biol. Chem. 2011, 286,
38298.
14. Zeng, J.; Vedachalam, S.; Xiang, S.; Liu, X.-W. Org. Lett. 2010, 13, 42.
15. Kolympadi, M.; Fontanella, M.; Venturi, C.; Andre, S.; Gabius, H. J.; Jiménez-
Barbero, J.; Vogel, P. Chem. Eur. J. 2009, 15, 2861.
16. Classon, B.; Liu, Z.; Samuelsson, B. J. Org. Chem. 1988, 53, 6126.
17. Garneau, S.; Qiao, L.; Chen, L.; Walker, S.; Vederas, J. C. Bioorg. Med. Chem. 2004,
12, 6473.
9. Lee, S. S.; Hong, S. Y.; Errey, J. C.; Izumi, A.; Davies, G. J.; Davis, B. G. Nat. Chem.
Biol. 2011, 7, 631.
10. Nasomjai, P.; O’Hagan, D.; Slawin, A. M. Beilstein J. Org. Chem. 2009, 5, 37.
11. Morales, J. C.; Zurita, D.; Penadés, S. J. Org. Chem. 1998, 63, 9212.
12. Wessel, H. P.; Mayer, B.; Englert, G. Carbohydr. Res. 1993, 242, 141.
13. Panchadhayee, R.; Misra, A. K. J. Carbohydr. Chem. 2010, 29, 76.
18. Chiara, J. L.; Bobo, S.; Sesmilo, E. Synthesis 2008, 19, 3160.
19. Webb, M. R. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4884.
20. Caravano, A.; Vincent, S. P. Eur. J. Org. Chem. 2009, 11, 1771.
21. Braitsch, M.; Kählig, H.; Kontaxis, G.; Fischer, M.; Kawada, T.; Konrat, R.;
Schmid, W. Beilstein J. Org. Chem. 2012, 8, 448.